Paromomycin - PharmaKB

Paromomycin

Paromomycin (paromomycin) is a small molecule pharmaceutical. Paromomycin was first approved as Humatin on 1982-01-01. It is used to treat amebiasis, cryptosporidiosis, and protozoan infections in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
digestive system diseases	D004066
animal diseases	D000820

Trade Name

FDA

EMA

Paromomycin (discontinued: Humatin, Paromomycin)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
care science essential first aid	C200263	2024-08-29
care science osha first aid	C200263	2024-02-05
emergency preparedness	OTC monograph final	2010-06-02
good neighbor pharmacy emergency preparedness and first aid contains 167 pieces	OTC monograph final	2010-06-11
humatin	ANDA	2023-01-10
madecassol	unapproved drug other	2019-10-08
paromomycin sulfate	ANDA	2017-11-07

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
cryptosporidiosis	—	D003457	A07.2
protozoan infections	—	D011528	B50-B64
amebiasis	EFO_0007144	D000562	A06

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

A: Alimentary tract and metabolism drugs

— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents

— A07A: Intestinal antiinfectives

— A07AA: Antibiotics, intestinal

— A07AA06: Paromomycin

HCPCS

No data

Clinical

Clinical Trials

1236 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Infections	D007239	EFO_0000544	—	14	25	40	63	58	194
Communicable diseases	D003141	—	—	6	19	22	23	32	98
Hiv infections	D015658	EFO_0000764	B20	11	23	33	8	20	91
Healthy volunteers/patients	—	—	—	59	2	1	7	8	76
Covid-19	D000086382	—	U07.1	6	26	31	4	11	70
Helicobacter infections	D016481	EFO_1000961	—	—	4	16	23	13	54
Pneumonia	D011014	EFO_0003106	J18	1	7	18	13	16	52
Mycobacterium avium-intracellulare infection	D015270	EFO_0007386	—	1	8	10	5	10	33
Mycobacterium infections	D009164	—	A31.9	1	9	11	2	11	32
Lung diseases	D008171	EFO_0003818	J98.4	1	6	10	9	3	28

Show 177 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lymphoma	D008223	—	C85.9	9	21	10	—	3	40
Multiple myeloma	D009101	—	C90.0	3	20	4	—	—	25
Large b-cell lymphoma diffuse	D016403	—	C83.3	6	11	7	—	—	21
B-cell lymphoma	D016393	—	—	8	9	5	—	1	21
Plasma cell neoplasms	D054219	—	—	2	15	4	—	—	20
Leukemia	D007938	—	C95	5	11	1	—	3	19
Cutaneous leishmaniasis	D016773	—	B55.1	1	11	5	—	2	16
Falciparum malaria	D016778	EFO_0007444	B50	1	12	8	—	—	15
Pulmonary tuberculosis	D014397	EFO_1000049	A15	—	9	4	—	2	14
Coronavirus infections	D018352	EFO_0007224	B34.2	1	6	6	—	1	13

Show 103 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Neoplasms	D009369	—	C80	8	6	—	—	2	15
Myeloid leukemia acute	D015470	—	C92.0	7	8	—	—	—	12
Myelodysplastic syndromes	D009190	—	D46	4	9	—	—	—	11
B-cell lymphoma marginal zone	D018442	—	C88.4	1	5	—	—	3	9
Myeloid leukemia	D007951	—	C92	4	4	—	—	1	8
Precursor cell lymphoblastic leukemia-lymphoma	D054198	—	C91.0	1	6	—	—	1	7
Squamous cell carcinoma of head and neck	D000077195	—	—	1	6	—	—	—	6
Chronic hepatitis b	D019694	EFO_0004239	B18.1	1	6	—	—	—	6
Cryptosporidiosis	D003457	—	A07.2	1	2	—	—	3	5
Bcr-abl positive chronic myelogenous leukemia	D015464	EFO_0000340	—	1	4	—	—	1	5

Show 148 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Drug interactions	D004347	—	—	8	—	—	—	—	8
Bacterial eye infections	D015818	—	—	5	—	—	—	—	5
Long qt syndrome	D008133	HP_0001657	I45.81	1	—	—	—	2	3
Kidney diseases	D007674	EFO_0003086	N08	1	—	—	—	2	3
Prostatic neoplasms	D011471	—	C61	1	—	—	—	2	3
Depressive disorder	D003866	EFO_1002014	F32.A	1	—	—	—	2	3
Chronic renal insufficiency	D051436	—	N18	1	—	—	—	1	2
Autoimmune diseases	D001327	EFO_0000540	M30-M36	2	—	—	—	—	2
Myelomonocytic leukemia acute	D015479	—	C92.5	1	—	—	—	1	2
Major depressive disorder	D003865	EFO_0003761	F22	1	—	—	—	1	2

Show 33 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Mycoplasma pneumonia	D011019	EFO_0007387	J15.7	—	—	—	—	6	6
Mycoplasma pneumoniae	D009177	—	B96.0	—	—	—	—	3	3
Dermatitis	D003872	—	L30.9	—	—	—	—	3	3
Apnea	D001049	—	R06.81	—	—	—	—	3	3
Hypertension	D006973	EFO_0000537	I10	—	—	—	—	2	2
Hyperaldosteronism	D006929	—	E26	—	—	—	—	2	2
Drug-related side effects and adverse reactions	D064420	—	T88.7	—	—	—	—	2	2
Nutrition disorders	D009748	EFO_0001069	—	—	—	—	—	2	2
Opportunistic infections	D009894	—	—	—	—	—	—	2	2
Staphylococcal infections	D013203	—	A49.01	—	—	—	—	2	2

Show 134 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Paromomycin
INN	paromomycin
Description	Paromomycin sulfate is an aminoglycoside sulfate salt resulting from the treatment of paromomycin with sulfuric acid. A broad-spectrum antibiotic, it is used for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis. It has a role as an antibacterial drug, an antiprotozoal drug, an anthelminthic drug and an antiparasitic agent. It is functionally related to a paromomycin.
Classification	Small molecule
Drug class	antibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O